Dr. Zhu on Primary Resistance to Osimertinib in EGFR-Mutant NSCLC
May 8th 2019You-cai Zhu, MD, PhD, Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, discusses primary resistance to osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).
Read More